M&A - BIOS Fund II, LP
Form Type: SCHEDULE 13D/A
Filing Date: 2025-05-08
Corporate Action: Acquisition
Type: Update
Accession Number: 000110465925046280
Filing Summary: On May 2, 2025, the transactions described in the Warrant Exchange Agreement were completed, whereby Bios Clinical Opportunity Fund, LP (Bios COF) acquired 1,148,482 pre-funded warrants in exchange for the cancellation of existing Series A and Series B warrants, along with a cash payment. The Pre-Funded Warrants, which enable the purchase of common stock, are immediately exercisable but subject to a 9.99% beneficial ownership limitation. This update also notes that various entities under the BIOS umbrella hold significant shares of common stock, with shared voting and dispositive powers across multiple funding partnerships. The document identifies several key persons and entities, along with their respective ownership percentages and the implications of these shareholdings on voting power within the company.
Additional details:
Shareholder Name: Bios Fund II, LP
Shares Held: 574432
Shareholder Name: Bios Fund II QP, LP
Shares Held: 1876624
Shareholder Name: Bios Fund II NT, LP
Shares Held: 251211
Shareholder Name: BIOS Incysus Co-Invest I, LP
Shares Held: 997433
Shareholder Name: Bios Fund III, LP
Shares Held: 570724
Shareholder Name: Bios Fund III QP, LP
Shares Held: 3727597
Shareholder Name: Bios Fund III NT, LP
Shares Held: 601980
Shareholder Name: Bios Clinical Opportunity Fund, LP
Shares Held: 3140803
Shareholder Name: BP Directors, LP
Shares Held: 121775
Shareholder Name: Bios Equity Partners, LP
Shares Held: 121775
Shareholder Name: Bios Equity Partners II, LP
Shares Held: 3699700
Shareholder Name: CAVU Management, LP
Shares Held: 8721776
Shareholder Name: Bios Capital Management, LP
Shares Held: 9120073
Shareholder Name: CAVU Advisors, LLC
Shares Held: 8721776
Shareholder Name: Bios Advisors GP, LLC
Shares Held: 9120073
Shareholder Name: Leslie W. Kreis
Shares Held: 8721776
Shareholder Name: Aaron G.L. Fletcher
Shares Held: 9120073
Comments
No comments yet. Be the first to comment!